NIH Launches Large TB Prevention Trial for People Exposed to Multidrug-Resistant TB
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB. Study participants are at high risk for MDR-TB because they either have latent TB infection, immune systems suppressed by HIV or other factors, or are younger than age 5 years and therefore have a weak immune system.
Emerging Antimicrobials and Diagnostics in AMR 2019
International Matchmaking Symposium on 19-20 November, 2019 in Amsterdam, The Netherlands.